The environmental fate of the antiviral drug oseltamivir carboxylate in different waters

Science of the Total Environment

Volumn 405, Issue 1-3, 2008, Pages 215-225

  Bartels, Peter ^a   von Tümpling Jr , Wolf ^a  

^a HELMHOLTZ CENTRE FOR ENVIRONMENTAL RESEARCH UFZ   (Germany)

Author keywords

Avian influenza; H5N1; Microbial degradation; Pharmaceuticals; Photolysis; Tamiflu

Indexed keywords

CHEMOTHERAPY; DRUG DELIVERY; DRUG DOSAGE;

ANTI-VIRAL DRUGS; AVIAN INFLUENZA; ENVIRONMENTAL FATE; H5N1; MICROBIAL DEGRADATION; OSELTAMIVIR; PHARMACEUTICALS; PHOTOLYSIS; TAMIFLU;

CARBOXYLATION;

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; RIVER WATER;

CATCHMENT; DRUG; ENVIRONMENTAL FATE; INFLUENZA; METABOLISM; PERSISTENCE; PHOTOLYSIS; RIVER POLLUTION; SURFACE WATER; WATERSHED; WORLD HEALTH ORGANIZATION;

ANTIVIRAL RESISTANCE; AQUATIC ENVIRONMENT; ARTICLE; DRUG DEGRADATION; ENVIRONMENTAL IMPACT; INFLUENZA VIRUS A H5N1; MICROBIAL DEGRADATION; MICROBIAL METABOLISM; PHOTOLYSIS; PRIORITY JOURNAL; UNITED KINGDOM; UNITED STATES; WORLD HEALTH ORGANIZATION;

ANTIVIRAL AGENTS; BIODEGRADATION, ENVIRONMENTAL; DRUG RESISTANCE, VIRAL; INFLUENZA A VIRUS, H5N1 SUBTYPE; OSELTAMIVIR; PHOTOLYSIS; RIVERS; WATER; WATER MICROBIOLOGY; WATER POLLUTANTS, CHEMICAL;

EURASIA; EUROPE; UNITED KINGDOM; WESTERN EUROPE;

AVES; AVIAN INFLUENZA VIRUS; ORTHOMYXOVIRIDAE;

EID: 52949112247     PISSN: 00489697     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.scitotenv.2008.06.032     Document Type: Article

References (31)

1. Accinelli C., Caracciolo A.B., and Grenni P. Degradation of the antiviral drug oseltamivir carboxylate in surface water samples. Int J Environ Anal Chem 87 (2007) 579-587
2. Andreozzi R., Raffaele M., and Nicklas P. Pharmaceuticals in STP effluents and their solar photodegradation in aquatic environment. Chemosphere 50 (2003) 1319-1330
3. Anesio A.M., Granéli W., Aiken G.R., Kieber D.J., and Mopper K. Effect of humic substance photodegradation on bacterial growth and respiration in lake water. Appl Environ Microb 71 (2005) 6267-6275
4. Arnold W.A., and McNeill K. Transformation of pharmaceuticals in the environment: photolysis and other abiotic processes. In: Petrovic M., and Barcelo D. (Eds). Analysis, fate and removal of pharmaceuticals in the water cycle. Comprehensive Analytical Chemistry vol. 50 (2007), Elsevier, Amsterdam 361-385
5. Bartels P., and von Tümpling W. Solar radiation influence on the decomposition process of diclofenac in surface waters. Sci Total Environ 374 (2007) 143-155
6. BBC News. Bird flu: country preparations. 02.21.2006: http://news.bbc.co.uk/1/hi/health/4380014.stm (28.05.2008).
7. Buser H.R., Poiger T., and Müller M.D. Occurrence and fate of the pharmaceutical drug diclofenac in surface waters: rapid photodegradation in a lake. Environ Sci Technol 32 (1998) 3449-3456
8. Eisenberg E.J., and Cundy K.C. High-performance liquid chromatographic determination of GS4071, a potent inhibitor of influenza neuraminidase, in plasma by precolumn fluorescence derivatization with naphthalenedialdehyde. J Chromatogr, B, Biomed Sci Appl 716 (1998) 267-273
9. EMEA (European Medicines Agency). Tamiflu: European public assessment report. Scientific discussion. 2005. http://www.emea.europa.eu/humandocs/PDFs/EPAR/tamiflu/136102en6.pdf (28.02.2008).
10. Fick J., Lindberg R.H., Tysklind M., Haemig P.D., Waldenström J., Wallensten A., and Olsen B. Antiviral oseltamivir is not removed or degraded in normal sewage water treatment: implications for development of resistance by influenza A virus. PLoS ONE 2 (2007) e986
11. Gerdil C. The annual production cycle for influenza vaccine. Vaccine 21 (2003) 1776-1779
12. Govorkova E.A., Leneva I.A., Goloubeva O.G., Bush K., and Webster R.G. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob Agents Chemother 45 (2001) 2723-2732
13. Gubareva L.V., Kaiser L., and Hayden F.G. Influenza virus neuraminidase inhibitors. Lancet 355 (2000) 827-835
14. Hayden F.G., Treanor J.J., Fritz R.S., Lobo M., Betts R.F., Miller M., Kinnersley N., Mills R.G., Ward P., and Straus S.E. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. J Am Med Assoc 282 (1999) 1240-1246
15. He G., Massarella J., and Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet 37 (1999) 471-484
16. Hoffmann-L Roche Inc.: Pandemic planning toolkit - what is Tamiflu?: http://www.pandemictoolkit.com/about-tamiflu/about-whatistamiflu.aspx (02.20.2008).
17. ® and generic versions. J Pharm Biomed 44 (2007) 1008-1013
18. Leneva I.A., Roberts N., Govorkova E.A., Goloubeva O.G., and Webster R.G. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antivir Res 48 (2000) 101-115
19. ®. J Pharm Biomed 42 (2006) 430-433
20. Mai Le Q., Kiso M., Someya K., Sakai Y.T., Nguyen T.H., Nguyen K.H.L., Pham N.D., Ngyen H.H., Yamada S., Muramoto Y., Horimoto T., Takada A., Goto H., Suzuki T., Suzuki Y., and Kawaoka Y. Avian flu: isolation of drug-resistant H5N1 virus. Nature 437 (2005) 1108
21. Massarella J.W., He G.Z., Dorr A., Nieforth K., Ward P., and Brown A. The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (Ro 64-0796/GS4104) in healthy adult and elderly volunteers. J Clin Pharmacol 40 (2000) 836-843
22. Normile D., and Enserink M. Avian influenza: with change in the seasons, bird flu returns. Science 315 (2007) 448
23. Singer A.C., Nunn M.A., Gould E.A., and Johnson A.C. Potential risks associated with the proposed widespread use of Tamiflu. Environ Health Perspect 115 (2007) 102-106
24. Snell P., Oo C., Dorr A., and Barrett J. Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids. Br J Clin Pharmacol 54 (2002) 372-377
25. SRU German Advisory Council on the Environment, Berlin, Germany. Statement No. 12, 2007: Pharmaceuticals in the environment. http://www.umweltrat.de/english/edownloa/statemen/Stellung_Pharmaceuticals_in_the_Environment_2007_eng.pdf (22.02.2008).
26. von Itzstein M. The war against influenza: discovery and development of sialidase inhibitors. Nat Rev Drug Discov 6 (2007) 967-974
27. von Itzstein M., Wu W.Y., Kok G.B., Pegg M.S., Dyason J.C., Jin B., Phan T.V., Smythe M.L., White H.F., Oliver S.W., Colman P.M., Varghese J.N., Ryan D.M., Woods J.M., Bethell R.C., Hotham V.J., Cameron J.M., and Penn C.R. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363 (1993) 418-423
28. Ward P., Small I., Smith J., Suter P., and Dutkowski R. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother 55 (2005) i5-i21
29. WHO: Cumulative Number of Confirmed Human Cases of Avian Influenza A/(H5N1) Reported to WHO (February 15th 2008): http://www.who.int/csr/disease/avian_influenza/country/cases_Table_2008_02_15/en/index.html (20.02.2008).
30. Wiltshire H., Wiltshire B., Citron A., Clarke T., Serpe C., Gray D., and Herron W. Development of a high-performance liquid chromatographic-mass spectrometric assay for the specific and sensitive quantification of Ro 64-0802, an anti-influenza drug, and its pro-drug, oseltamivir, in human and animal plasma and urine. J Chromatogr, B, Biomed Sci Appl 745 (2000) 373-388
31. Zepp R.G., and Cline D.M. Rates of direct photolysis in aquatic environment. Environ Sci Technol 11 (1977) 359-366